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Abstract
Introduction
Conformational disorders such as 
Alzheimer’s, Parkinson’s, familial 
amyloidotic polyneuropathy and 
spongiform encephalopaties are 
a consequence of protein misfold-
ing and aggregation predominantly 
in the form of amyloid ϐibrils. These 
pathologies represent a major health 
problem, which most probably will 
overwhelm the health systems of 
developed countries in the near 
future. Signiϐicant progress has been 
made recently to understanding the 
underlying mechanism of protein 
misfolding and aggregation. The cur-
rent picture of protein aggregation is 
a phenomenon resulting from protein 
conformational ϐluctuations leading 
to misfolded intermediates prone to 
form non-native interactions with 
other intermediates, resulting in 
amyloid ϐibril formation. Fortunately 
just a small group of proteins are 
associated with human conforma-
tional disorders. The primary causes 
that lead this group of proteins to 
misfolding and aggregation are point 
mutations, protein over-expression 
and failure of protein quality-control 
system. Beside amyloid formation, 
there are other types of aggregation 
available to a misfold-disease-related 
polypeptide chain in the protein-
free energy landscape. Among them, 
native-like aggregation is becoming a 
widely studied topic of research. This 
aggregation type, simultaneously 
straightforward and ubiquitous, 
seems to be involved concurrently in 
the pathway of amyloid ϐibril forma-
tion and disruption. In this review, the 
pathways of misfold and aggregation 
of a protein are accessed along with 
the primary causes that turn a native 
soluble protein into amyloid ϐibrils 
or native-like aggregate. In addition, 
an insight into the biophysical and 
biochemical aspects fundamental to 
amyloid ϐibril formation and native-
like aggregation is provided. Finally 
some clues are presented about what 
makes a protein follow an amyloi-
dogenic or native-like aggregation 
pathway.
Conclusion
More laboratory data should be gath-
ered about the structure, stability, 
dynamics and aggregation kinetics, 
in order to get a clearer picture of the 
biophysical mechanisms underlying 
native-like aggregation.
Introduction
Globular proteins rapidly fold 
into a well-deϐined three-dimen-
sional structure after synthesis in 
a cell endoplasmic reticulum (ER). 
However, under some conditions 
proteins do not fold correctly into 
their native structure. This malfunc-
tion might result in a set of mala-
dies called protein conformational 
 disorders or misfolding diseases1. 
These pathologies are called this due 
to the structural modiϐications that 
can occur during the lifetime events 
of a protein. Amyloidoses are  subset 
of  misfolding diseases, compris-
ing pathologies such as Alzheimer’s, 
Parkinson’s, familial amyloidotic 
polyneuropathy and spongiform 
encephalopaties, which result from 
 misfolding of protein precursors and 
amyloid ϐibril formation.
One exquisite and contemporary 
way of describing the different three-
dimensional states accessible to a 
polypeptide chain is the protein-free 
energy landscape2. This has allowed 
scientists to grasp the protein fold-
ing, misfolding and aggregation 
mechanisms3.
The features of a protein-free energy 
landscape depend mostly on the amino 
acid sequence, post-translational mod-
iϐications, ligands, cofactors and envi-
ronmental conditions4,5. After being 
synthesized a polypeptide chain usu-
ally folds into its native state, the lower 
free energy value of the landscape2 
(Figure 1). However, under physi-
ological conditions, a small group of 
peptides and proteins evolve into non-
native folds, partially or total unfolds 
and aggregates6. This can be seen as a 
modiϐication in the shape of proteins 
free energy landscape (Figure 2).
The primary causes driving this 
reshaping are point mutations or pro-
tein over-expression7. Point mutations 
result in protein sequence modiϐica-
tions favouring ϐibrillation by crowding 
protein partially unfolded states, which 
are prone to form aggregates8,9. In that 
case, the protein free energy landscape 
is reshaped in such a way that it sta-
bilizes protein-folding intermediates 
(Figure 2). Consequently, the incre-
ment on the concentration of interme-
diates can lead to aggregation. On the 
other hand, protein  over-expression 
increases the concentration of poly-
peptide chains driving the polypeptide 
chain into an  aggregation pathway 
as well. It is  noteworthy that fold-
ing of a monomeric protein is a zero-
order reaction whereas aggregation 
is at least a ϐirst-order  reaction10. This 
means that increasing protein con-
centration may force a protein into an 
aggregation route.
What drives an amyloid protein precursor from an 
 amyloidogenic to a native-like aggregation pathway?
A Quintas*
*Corresponding author
Email: alexandre.quintas@gmail.com
Centro de Investigação Interdisciplinar Egas 
Moniz, Instituto Superior das Ciências da 
Saúde Egas Moniz, Campus Universitário, 
Qta. da Granja, Monte da Caparica, 2829-511 
Caparica, Portugal
Page 2 of 8
Review
Co
m
pe
Ɵ n
g 
in
te
re
st
s:
 n
on
e 
de
cl
ar
ed
. C
on
fl i
ct
 o
f i
nt
er
es
ts
: n
on
e 
de
cl
ar
ed
.
A
ll 
au
th
or
s 
co
nt
rib
ut
ed
 to
 th
e 
co
nc
ep
t o
n,
 d
es
ig
n,
 a
nd
 p
re
pa
ra
Ɵ o
n 
of
 th
e 
m
an
us
cr
ip
t,
 a
s 
w
el
l a
s 
re
ad
 a
nd
 a
pp
ro
ve
d 
th
e 
fi n
al
 m
an
us
cr
ip
t.
A
ll 
au
th
or
s 
ab
id
e 
by
 th
e 
A
ss
oc
ia
Ɵ o
n 
fo
r M
ed
ic
al
 E
th
ic
s 
(A
M
E)
 e
th
ic
al
 ru
le
s 
of
 d
is
cl
os
ur
e.
Licensee OA Publishing London 2013. Creative Commons Attribution Licence (CC-BY)
FĔė ĈĎęĆęĎĔē ĕĚėĕĔĘĊĘ: Quintas A. What drives an amyloid protein precursor from an amyloidogenic to a native-like 
aggregation pathway? OA Biochemistry 2013 Mar 01;1(1):6.
Beside mutation and protein over-
expression, oxidative stress, activation 
of signalling pathways from quality 
control systems and post-translation 
modiϐications may act as inductors of 
protein aggregation11. The accumula-
tion of toxic aggregates might dam-
age the cells and progress to intra- or 
extra-cellular amyloid deposits1.
Recent studies with the amyloi-
dogenic proteins β-2-microglobulin, 
insulin and stefin B have shown 
that native-like aggregation might 
be associated with conformational 
diseases12-14. Indeed, some authors 
suggest that amyloidogenesis under 
physiological conditions follows a 
native-like folding aggregation12, 
whereas others argue that it must 
follow a misfolding pathway13,14. 
In spite of the lack of consensus 
about native-like aggregation, these 
investigations highlight the diver-
sity of routes that might happen in 
conformational disorders. Despite 
this, it must be emphasized that 
native-like aggregates per se have 
been associated with cellular tox-
icity15. This meaningful research 
is opening new avenues into the 
understanding of non-amyloid 
aggregation types in human dis-
eases. The aim of this review was 
to discuss what drives an amyloid 
protein precursor from an amyloi-
dogenic to a native-like aggregation 
pathway.
Conformational disorders and 
amyloid ϐibril formation
From the tens of thousands of human 
proteins just 40 are currently known 
to be associated with amyloid for-
mation. Amyloid ϐibrils are well-
organized protein aggregates that 
bind to congo red and thioϐlavin 
dyes. Morphologically, these ϐibrils 
have a variable length and a  diameter 
between 6 and 12 nm, displaying a 
characteristic cross-β structure per-
pendicularly oriented to the  ϐibber 
axis16,17. The amyloid ϐibril low- 
resolution crystal structure shows a 
periodic β-sheet stacking stabilized 
by hydrogen bonds forming a packed 
zipper structure, the core of the 
ϐibre18.
Along with morphological stud-
ies, the understanding of amyloid 
ϐibril formation kinetics is funda-
mental. Several models have been 
proposed to explain amyloid ϐibril 
formation kinetics. The classical 
kinetic view for amyloidogenesis 
describes amyloid ϐibril formation 
as a nucleation-dependent process 
with three distinct steps: (i) the lag 
phase, which is associated with the 
formation of the seed; (ii) the elon-
gation phase, where the ϐibril growth 
takes place; and (iii) the ϐinal steady-
state phase19.
The mechanism by which the 
nucleation process starts usually 
involves the native polypeptide 
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Figure 1: Schematic representation of protein free-energy landscape. Native 
state corresponds to bottom of the funnel (lowest free-energy value). Partially 
fold intermediates have higher free-energy values.
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Figure 2: Schematic representation of protein free-energy landscape where 
aggregation is an accessible pathway. The reshaping of the free-energy 
 landscape occurs due to point mutation, covalent modiϐication and oxidative 
stress, among others.
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precursor undergoing conforma-
tional changes that lead to the 
 formation of a partially unfolded 
β-sheet-rich intermediate prior to 
aggregation and nucleus formation20. 
These conformational modiϐications 
depend on the initial structural fea-
tures of the native precursor. The 
elongation phase occurs through 
addition of monomeric units to the 
nuclei or stacking of small ϐibrils.
All major protein-fold motifs 
and protein hierarchical levels are 
represented in amyloid precursor 
 proteins6. In this review oligomeric, 
monomeric and intrinsically unstruc-
tured proteins (IUP) amyloid precur-
sor are discussed independently.
Oligomeric protein as amyloid 
precursors
Familial amyloidosis polyneuropa-
thy (FAP), senile systemic amyloi-
dosis (SSA) and amyotrophic lateral 
sclerosis (ALS) are conformational 
diseases involving multi-subunits 
of all-beta native-state precursors. 
In FAP and SSA the precursors are 
transthyretin variants and wild-
type transthyretin (TTR) and in ALS 
the precursors are superoxide dis-
mutase variants (SOD).
Human TTR is a homo-tetrameric 
protein with an eight-stranded 
β-sandwich motif in each subunit. 
Wilde-type TTR is associated with 
SSA, a degenerative disorder affect-
ing predominantly individuals aged 
above 80 years. Variants of TTR 
are associated to FAP, an autosomic 
dominant degenerative disease. 
Depending on the TTR variant, the 
disease can have an earlier onset. 
In FAP, the physiological model for 
amyloid ϐibril formation establishes 
that amyloid formation by TTR is 
triggered by irreversible tetramer 
dissociation to a compact non-
native monomer. Depending on its 
thermodynamic stability, the non-
native monomer originates partially 
unfolded species with a high ten-
dency for ordered aggregation into 
amyloid ϐibrils8,21,22. Interestingly, 
the amyloidogenic potential of 
TTR variants seems to correlate to 
their tendency to produce partially 
unfolded monomeric species8. There 
is very little knowledge regarding 
amyloid ϐibril formation from oligo-
meric proteins, and the few models 
found in the literature indicate that 
dissociation and thermodynamic 
instability of the resulting mono-
mers are the primary causes behind 
the formation of amyloid ϐibrils 
(Figure 3).
Monomeric proteins as amyloid 
precursors
A group of monomeric proteins or 
its variants, such as lysozyme, cys-
tatin C, immunoglobulin light chain, 
prolactin, insulin, lactoferrin and 
γ-crystallin, suffer conformational 
changes prior to amyloid ϐibril forma-
tion23. Human lysozyme is used as an 
example of monomeric amyloid pro-
tein precursor.
Human lysozyme is a small mono-
meric protein that belongs to the α+β 
motif with two structural domains, an 
alpha-domain with four alpha-helices 
and one 3
10
 helix, and a beta domain, 
which consists mainly in an anti-
parallel β-sheet. Several lysozyme 
variants are associated with a familial 
non-neuropathic amyloidosis, which 
eventually forms amyloid deposits 
in the liver, spleen and kidneys24,25. 
Comparative conformational stability 
studies between wild-type lysozyme 
and its amyloidogenic variants 
have shown that the native states of 
pathogenic variants are signiϐicantly 
less stable when compared to the 
wild-type protein26. Experimental 
data have shown that a lesser con-
formational stability of lysozyme 
variant correlates to a more amyloi-
dogenic behaviour27. The suggested 
molecular mechanism of ϐibrillation 
of amyloidogenic variants of human 
lysozyme points to the native states 
in dynamic equilibrium with partially 
unfolded species. In turn, the partially 
unfolded intermediates of lysozyme 
can undergo self-association, lead-
ing to formation of β-sheet ordered 
aggregates and, eventually, amyloid 
ϐibrils27.
Native Tetramer
Non-Native Monomer Amyloidogenic
Intermediate
Partially Unfold
Speciese
Unfold State
Amyloid Fibrils
Nucleous
Figure 3: Schematic representation 
of pathways for amyloid ϐibril for-
mation from a homo-tetrameric pro-
tein precursor according to Quintas 
et al.8. The oligomeric protein in its 
native state dissociates into a non-
native monomer. The non-native 
monomeric species formed from dis-
sociation may undergo several con-
formational changes due to a lack of 
conformational stability. As a result 
of hydrophobic exposition, these 
species may associate to form aggre-
gates that eventually form amyloid 
ϐibrils.
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Figure 4 presents possible amyloi-
dogenic paths from native  structure 
to different putative intermedi-
ates and, ϐinally, to amyloid ϐibril 
formation.
Intrinsically unfolded protein as amy-
loid precursors
After ribosomal synthesis, the fold-
ing pathway of globular proteins is 
overcome with a delicate balance 
between the hydrophobic effects, 
non- covalent interactions such as 
hydrogen bonds and conϐigurational 
entropy. The later is the negative 
counter-balance of forces involved in 
protein folding. However, IUP show 
a low overall hydrophobicity and a 
large net charge. Consequently, the 
major driving effect in the folding 
pathway is conϐigurational entropy, 
which may surpass the hydropho-
bic effect. This balance impels the 
polypeptide chain into a native dis-
ordered state28. Although the general 
underlying molecular mechanisms 
of amyloidogenesis for globular pro-
teins are associated with protein 
misfolding, IUP must go through a 
partial folding in order to undergo 
aggregation and amyloid ϐibril 
formation29.
The triggering cause for partial 
folding and amyloid ϐibril formation 
seems to be related to (i) natural 
propensity to form β-sheet inter-
mediates; (ii) covalent modiϐication, 
which may lead to the development of 
local structure; or (iii) protein over-
expression, which may lead to aggre-
gation simultaneously with β-sheet 
formation30.
α-synuclein is an IUP associated 
with Parkinson’s disease (PD), a 
movement disorder characterized 
by degeneration of dopaminergic 
neurons in the substantia nigra in 
the brain31. α-synuclein amyloid 
ϐibril formation seems to occur in 
the form of partially folded interme-
diate, pre-molten globule-like struc-
ture, the ϐirst step for ϐibrillization31 
(Figure 5).
Conformational disorders and 
native-like aggregation
A key question regarding patholo-
gies involving protein aggregation 
and deposition is the mechanism 
by which such protein precursors 
are transformed from their native 
state into high-ordered aggregates. 
There are two major pathways that 
have been identiϐied till date. The 
amyloidogenic route, as previously 
Native Monomer
Amyloidogenic
Partially Unfold
Intermediate
Putatively
Intermediate
Nucleous
Unfold State
Amyloid Fibrils
Figure 4: Schematic representation 
of molecular pathways for amyloid 
ϐibril formation from a monomeric 
protein precursor. Due to its lesser 
conformational stability, mono-
meric protein in its native state can 
populate partial unfolded states 
that in turn can form amyloidogenic 
intermediates with high propensity 
for aggregation. Eventually, these 
intermediates lead to amyloid ϐibril 
formation.
Partial
Folding
Intrinsically
Unstructured
Protein
Amyloidogenic
Intermediate
Nucleous
Amyloid Fibrils
Figure 5: Schematic representation 
of the molecular pathways of amyloid 
ϐibril formation from an IUP precur-
sor. The IUP partial folds into a β-sheet 
intermediate. This may starts to aggre-
gate and eventually progress to amy-
loid ϐibrils.
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mentioned, is where aggregation 
starts from misfolded conformational 
states of proteins, and the native-like 
aggregation pathway is where aggre-
gation of normally globular proteins 
may occur directly from native states 
via mutations, thermal ϐluctuations, 
protein concentration or post-trans-
lational modiϐications13,32,33. Unlike 
amyloidogenesis, native-like aggre-
gation pathways do not present an 
unfolding specie to trigger oligomeri-
zation33,34. In fact, native-like aggre-
gation seems to proceed by stacking 
of near-native protein intermediates 
towards oligomeric species of ϐinite 
size32,33 (Figure 6).
In humans, native-like aggrega-
tion has been described in a very 
small group of proteins. Among them 
β-2-microglobulin is associated with 
 dialysis-related amyloidosis, factor 
VIII to haemophilia A, and insulin to 
insulin-injection amyloidosis12,13,35. 
One study with β-2-microglobin 
suggests that amyloid ϐibril forma-
tion occurs through self-assembly 
of native-like intermediates12. Pisal 
et al. showed that native-like aggre-
gates of factor VIII are signiϐicantly 
more immunogenic than the non- 
aggregated monomeric form36. 
Oliveira et al. showed that post-folding 
modiϐication of insulin with methylg-
lyoxal inhibits formation and growth 
of insulin amyloid ϐibrils, blocking 
the seeding nuclei13. Interestingly, 
β-2-microglobulin is an all-beta motif 
protein whereas insulin is an all-alpha 
motif protein. This suggests that 
depending on the  protein precursor 
fold class, native-like aggregation may 
proceed to amyloid-like ϐibrils.
A very interesting ϐinding by Deva 
et al. show that native-like aggrega-
tion may inhibit ribosomal protein S6 
from Thermus thermophilus to form 
amyloid. However, a very high pro-
tein  concentration must be reached. 
According to the authors33, the 
 off-pathway towards native-like aggre-
gates overrules amyloid ϐibril forma-
tion at high protein concentration. It 
Unfold State
Native Monomer
Protein Covalent
Modification
Amyloidogenic
Intermediate
Native-Like
Aggregation
Oligomer
Figure 6: Native-like aggregation model. The native protein can primarily fol-
low two different pathways. It can undergo a rapid equilibrium with a partial 
unfolded monomeric form, or it can irreversibly go through an aggregation 
pathway by sequential addition of glycated monomers in each step of the reac-
tion, as represented by the curve arrows. Based on Oliveira et al.37.
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seems that partial unfold intermediate 
formation makes the amyloidogenic 
pathway less favourable with the 
increment protein concentration33.
The association between native-
like aggregation and human disorders 
suggests that this is more  relevant 
than was thought.
What drives an  amyloidogenic 
protein into a native-like 
 aggregation pathway?
Recent observations have shown 
that amyloid proteins, such as β-2-
microglobulin, alpha-synuclein, insulin 
and ribosomal protein S6, can follow 
a native-like aggregation route12,13,33,37. 
Some of these proteins when cova-
lently modiϐied or in very high protein 
concentration environment change 
from an amyloid ϐibril formation path-
way to an native-like aggregation path-
way13,33,37. The native-like aggregation 
pathway seems to compete with the 
amyloid ϐibril pathway.
Oliveira et al. have investigated the 
effects of methylglyoxal modiϐication 
in insulin structure and ϐibril-forming 
properties. Circular dichroism studies 
showed that insulin glycation leads to 
native-like aggregation and that insu-
lin ϐibril formation is substantially 
reduced. In effect, the authors suggest 
that glycation impairs insulin confor-
mational alterations to the extent that 
they convert into an amyloidogenic 
intermediate, inhibiting the ϐibrilla-
tion process by blocking the formation 
of the seeding nuclei. Ultimately, ϐibril 
formation is reduced due to a lack of 
critical concentration of seeds13.
Deva et al. has shown a similar 
result in different environmental 
conditions with ribosomal protein 
S633. The authors state that when 
the concentration of ribosomal pro-
tein S6 is too high, the tendency is to 
form native-like aggregates instead 
of amyloid ϐibrils. According to the 
authors, amyloid ϐibrillation path-
way demands a structural rearrange-
ment of the monomeric specie into a 
pre-aggregation monomer before it 
starts to aggregate. This means there 
is a zero-order kinetics step before 
the aggregation into amyloid takes 
place in such a way that at very high 
concentration of protein, native-like 
aggregation, a pure ϐirst-order step, is 
favoured33.
Recently, a model for native-like 
aggregation of methylglyoxal-gly-
cated proteins has been proposed32. 
Native-like aggregation occurs due to 
localized protein structural changes 
leading to a decrease on the confor-
mational stability of the modiϐied 
protein. Interestingly, the decrease 
in the stability of monomeric specie 
is counterbalanced by the forma-
tion of native-like aggregates that 
are thermodynamically more stable. 
The same study observed that the 
formation of glycated cytochrome c 
unfolded species is an off-pathway 
of the native-like aggregation route. 
The authors suggest that glycation of 
amyloidogenic proteins may lead to a 
shift from an amyloidogenic pathway 
to a native-like aggregation through 
a process that is thermodynamically 
and kinetically favoured32.
Taking together the observations 
previously presented, what emerges 
is a preliminary picture of the driving 
forces that make an amyloidogenic 
protein follow a route of native-like 
aggregation. The ϐirst step into the 
native-like aggregation route points 
to the inhibition of amyloidogenic 
intermediate formation. This may 
happen due to hindrance of amy-
loidogenic sequences to aggregate 
after post-folding modiϐication of the 
protein precursor. The second step 
is the overcoming of protein free-
energy landscape barrier into native-
like aggregation. This might happen 
through a signiϐicant increment in 
protein concentration or by reducing 
the activation energy between native-
states and native-like aggregates. The 
second step can happen indepen-
dently of the ϐirst step.
Discussion
The authors have referenced some of 
their own studies in this review. The 
protocols of these studies have been 
approved by the relevant ethics com-
mittees related to the institution in 
which they were performed.
Understanding how amyloido-
genic proteins aggregate and form 
amyloid is a key issue in bringing 
light to understanding human con-
formational diseases and design-
ing novel therapeutic approaches. 
Amyloid ϐibril formation usually 
occurs through one of the following 
events: (i) defective protein folding 
pathway and formation of misfolding 
intermediates, (ii) partial unfolding of 
the native state due to lack of protein 
stability, (iii) defective folding due to 
overcrowding of polypeptide chains 
in the endoplasmic reticulum and 
(iv) overwhelming of the cell-folding 
quality-control systems8,19,38. Overall, 
the underlying molecular mecha-
nisms of aggregation into amyloid 
ϐibrils imply conformational changes 
of protein, disruption of native non-
covalent interactions35 and forma-
tion of aggregation-prone non-native 
intermediates21.
Until recently amyloid ϐibril for-
mation has been seen as a unique 
 aggregation pathway in human con-
formational disorders. However, 
native-like aggregation may play 
a signiϐicant role in physiological 
 processes. The biophysical mecha-
nism underlying this process is not 
yet fully understood. However, the 
consensus is that native-like aggre-
gation seems to proceed by stacking 
of near-native protein intermedi-
ates towards oligomeric species of 
ϐinite size. In addition, experimen-
tal data suggest that the native-like 
aggregation pathway competes with 
the  amyloid ϐibril pathway. Covalent 
modiϐications such as glycation can 
prevent the formation of amyloido-
genic intermediates, inhibiting the 
amyloidogenic pathway.
Conclusion
More laboratory data should be gath-
ered about the structure, stability, 
dynamics and aggregation kinetics in 
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order to get a clearer picture of the 
biophysical mechanisms underlying 
native-like aggregation.
Understanding what makes a pro-
tein follow an amyloid or a native-like 
aggregation pathway is essential to 
opening new avenues in therapeu-
tic approaches to conformational 
diseases.
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